Vivo Capital’s Bolt Biotherapeutics BOLT Stock Holding History

Vivo Capital’s Portfolio BOLT Stock Details BOLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$279K	Hold	72,414	–	–	0.03%	45
2026 Q1	$293K	Hold	72,414	–	–	0.02%	45
2025 Q4	$396K	Sell	72,414 -103,650	-59%	-$556K	0.03%	46
2025 Q3	$937K	Hold	176,064	–	–	0.08%	46
2025 Q2	$986K	Sell	176,064 -1	-0%	-$7	0.1%	41
2025 Q1	$1.41M	Hold	176,065	–	–	0.19%	36
2024 Q4	$1.88M	Hold	176,065	–	–	0.21%	36
2024 Q3	$2.28M	Hold	176,065	–	–	0.19%	35
2024 Q2	$2.64M	Hold	176,065	–	–	0.24%	34
2024 Q1	$4.93M	Hold	176,065	–	–	0.39%	35
2023 Q4	$3.94M	Sell	176,065 -17,500	-9%	-$341K	0.32%	38
2023 Q3	$4.03M	Hold	193,565	–	–	0.44%	37
2023 Q2	$4.96M	Hold	193,565	–	–	0.34%	36
2023 Q1	$5.38M	Hold	193,565	–	–	0.37%	33
2022 Q4	$5.03M	Hold	193,565	–	–	0.58%	34
2022 Q3	$5.73M	Hold	193,565	–	–	0.63%	36
2022 Q2	$7.9M	Hold	193,565	–	–	0.79%	28
2022 Q1	$10.6M	Hold	193,565	–	–	0.73%	29
2021 Q4	$19M	Hold	193,565	–	–	1.14%	21
2021 Q3	$49M	Hold	193,565	–	–	2.2%	11
2021 Q2	$59.9M	Hold	193,565	–	–	2.59%	10
2021 Q1	$127M	Buy	+193,565	New	+$126M	4.48%	8

Other funds holding BOLT

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

T3 Companies New York $93.7M AUM

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

NCNMGF

Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

Vivo Capital's BOLT Position: Q2 2026 in Review

Vivo Capital held its Bolt Biotherapeutics (BOLT) position steady in Q2 2026 at 72,414 shares worth $279K. The position accounts for 0.03% of the portfolio, ranked #45.

Vivo Capital first reported a position in BOLT in Q1 2021 and has held it in 22 quarters since. The position peaked at $127M in Q1 2021. 23 funds tracked by Wall St. Rank hold BOLT as of Q2 2026.

Vivo Capital held 72,414 shares of Bolt Biotherapeutics worth $279K as of Q2 2026.
Vivo Capital left its Bolt Biotherapeutics share count unchanged in Q2 2026.
Bolt Biotherapeutics made up 0.03% of Vivo Capital's portfolio in Q2 2026, its #45 holding.
Vivo Capital first reported a position in Bolt Biotherapeutics in Q1 2021 and has held it in 22 quarters since.
Vivo Capital's Bolt Biotherapeutics position peaked at $127M in Q1 2021.
23 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.